Published in Angew Chem Int Ed Engl on January 01, 2009
Organelle-specific activity-based protein profiling in living cells. Angew Chem Int Ed Engl (2014) 0.80
Targeted delivery of antigen processing inhibitors to antigen presenting cells via mannose receptors. ACS Chem Biol (2010) 0.80
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A (2005) 3.75
Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 3.70
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci U S A (2006) 2.71
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res (2011) 2.56
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Structural and mechanistic basis of pre- and posttransfer editing by leucyl-tRNA synthetase. Mol Cell (2003) 2.41
Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. Immunity (2011) 2.34
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol (2007) 2.21
Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes (2007) 2.01
MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol (2005) 1.70
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2005) 1.66
Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev (2003) 1.62
Thioglycosides in sequential glycosylation strategies. Chem Soc Rev (2005) 1.60
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun (2010) 1.55
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem (2006) 1.52
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion (2002) 1.52
Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res (2012) 1.49
Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J (2013) 1.48
Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
Synthesis of pH-activatable red fluorescent BODIPY dyes with distinct functionalities. Org Lett (2011) 1.44
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J (2011) 1.43
Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice. Atherosclerosis (2011) 1.42
Glycosphingolipids--nature, function, and pharmacological modulation. Angew Chem Int Ed Engl (2009) 1.41
Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol (2011) 1.31
Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem (2007) 1.28
Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2. Blood (2007) 1.27
Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res (2007) 1.27
Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol (2010) 1.26
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis (2011) 1.25
Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl (2003) 1.25
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol (2009) 1.24
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.21
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19
The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood (2003) 1.18
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res (2013) 1.18
Cinnamaldehyde and cinnamaldehyde derivatives reduce virulence in Vibrio spp. by decreasing the DNA-binding activity of the quorum sensing response regulator LuxR. BMC Microbiol (2008) 1.18
A modular strategy toward the synthesis of heparin-like oligosaccharides using monomeric building blocks in a sequential glycosylation strategy. J Am Chem Soc (2005) 1.17
A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol (2008) 1.17
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev (2002) 1.16
Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res (2009) 1.16
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology (2002) 1.16
Ins and outs of dendritic cells. Int Arch Allergy Immunol (2006) 1.16
Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem (2003) 1.16
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol (2012) 1.14
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood (2007) 1.13
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13
Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol (2008) 1.12
CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2007) 1.11
Thioglycuronides: synthesis and application in the assembly of acidic oligosaccharides. Org Lett (2004) 1.11
New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol (2012) 1.11
Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med (2011) 1.10
Design, synthesis, and evaluation of a lanthanide chelating protein probe: CLaNP-5 yields predictable paramagnetic effects independent of environment. J Am Chem Soc (2008) 1.09
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem (2008) 1.08
Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One (2009) 1.08
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer (2008) 1.07
6'-derivatised alpha-GalCer analogues capable of inducing strong CD1d-mediated Th1-biased NKT cell responses in mice. J Am Chem Soc (2008) 1.07
Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors. Org Biomol Chem (2007) 1.07
Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. J Lipid Res (2009) 1.07
Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol (2002) 1.07
Functional imaging of legumain in cancer using a new quenched activity-based probe. J Am Chem Soc (2012) 1.05
Total body ABCG1 expression protects against early atherosclerotic lesion development in mice. Arterioscler Thromb Vasc Biol (2007) 1.05
Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg Med Chem (2004) 1.05
The use of cyclic bifunctional protecting groups in oligosaccharide synthesis--an overview. Carbohydr Res (2006) 1.04
Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest (2003) 1.04
Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis. Am J Pathol (2007) 1.03
Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation (2003) 1.03
The Ku80 carboxy terminus stimulates joining and artemis-mediated processing of DNA ends. Mol Cell Biol (2008) 1.03
Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. Bioorg Med Chem Lett (2006) 1.03
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol (2008) 1.03
Automated solid-phase synthesis of β-mannuronic acid alginates. Angew Chem Int Ed Engl (2012) 1.02
2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem (2006) 1.02
Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t. Chem Biol (2010) 1.01
Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J Immunol (2002) 1.01
KLF2 suppresses TGF-beta signaling in endothelium through induction of Smad7 and inhibition of AP-1. Arterioscler Thromb Vasc Biol (2006) 1.01
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther (2008) 1.01
Proteasome activity profiling: a simple, robust and versatile method revealing subunit-selective inhibitors and cytoplasmic, defense-induced proteasome activities. Plant J (2009) 1.01